Pharmidex attending FENS Neuroscience conference
June 23, 2018
Pharmidex will be attending this years FENS neuroscience conference, where the CNS team will be presenting a poster.
Pharmidex will presenting "Dopamine metabolism in striatum, and rearing behaviour, suggest different significance on the attenuation of nicotine-induced changes on total locomotor activity for Varenicline and Baclofen."
The Abstract number for our presentation is F18-2414ABSTRACT. For more information please come and find our presentation as stated below!
Session Name: C. DISORDERS OF THE NERVOUS SYSTEM - C.15.l Psychiatric disorders: Addiction and drugs of abuse - part II
Date: 8 July 2018
Session Time: 14:00 - 17:30
Poster Board Number: C169
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
